Shares of Glaukos Corporation (GKOS) skyrocketed 23.88% in pre-market trading on Thursday, following the company's impressive third-quarter financial results and a flurry of analyst upgrades. The ophthalmic medical technology company's strong performance and positive outlook have ignited investor enthusiasm, driving the stock to significant gains.

Glaukos reported a narrower Q3 loss amid higher sales, demonstrating the company's improving financial health. The firm's record Q3 sales growth has caught the attention of Wall Street, with several analysts raising their price targets for GKOS stock. JP Morgan lifted its target price to $120 from $110, while BTIG increased its projection to $116 from $104. Other firms, including Citigroup, Needham, and Wells Fargo, also raised their targets, reflecting growing confidence in Glaukos' business prospects.

The surge in Glaukos' stock price underscores the market's positive reaction to the company's strong quarterly performance and the subsequent analyst endorsements. As the firm continues to demonstrate growth in its ophthalmic medical technology segment, investors appear increasingly optimistic about its future potential. With multiple analyst upgrades and a solid financial foundation, Glaukos seems well-positioned for continued success in the healthcare sector.